The U.S. Food & Drug Administration releases a list of pre-market approvals granted in November 2011.
Below are Premarket Approvals (PMA), Product Development Protocols (PDP), Supplement and Notice Decisions. This list is generated on a monthly basis.
PMA Original Approvals
|APPLICATION NUMBER / DATE of APPROVAL||DEVICE TRADE NAME||COMPANY NAME CITY, STATE, & ZIP||DEVICE DESCRIPTION / INDICATIONS|
|MelaFind®||MELA Sciences, Inc.
|Approval for the MelaFind device. MelaFind is intended for use on clinically atypical cutaneous pigmented lesions with one or more clinical or historical characteristics of melanoma, excluding those with a clinical diagnosis of melanoma or likely melanoma. MelaFind is designed to be used when a dermatologist chooses to obtain additional information for a decision to biopsy. MelaFind should NOT be used to confirm a clinical diagnosis of melanoma.
MelaFind is only for use by physicians trained in the clinical diagnosis and management of skin cancer (i.e., dermatologists) who have also successfully completed a training program in the
appropriate use of MelaFind.
The MelaFind result is one element of the overall clinical assessment. MelaFind positive
lesions (which may include malignant melanoma, melanoma in situ, high grade dysplastic nevi
and atypical melanocytic proliferation/hyper-plasia) should be considered for biopsy; the biopsy
decision of a MelaFind negative lesion should be based on the remainder of the entire clinical context. Lesions that are "non-evaluable" by MelaFind should be carefully re-evaluated for biopsy.
MelaFind is indicated only for use on lesions with a diameter between 2 mm and 22 mm,
lesions that are accessible by the MelaFind imager, lesions that are sufficiently pigmented (i.e. not for use on non-pigmented or skin-colored lesions), lesions that do not contain a scar or
RECENT BLOG POSTS
Kips Bay Medical turns to founder Villafana
Manny Villafana, who founded St. Jude Medical and Kips Bay Medical, joins a last-gasp, $3 million...
Johnson & Johnson taps Google for robot-assisted surgery program
Johnson & Johnson inks a deal with Google to develop a robot-assisted surgery device.
Cardica lays of 24% of workforce
Cardica says it will lay off about 24% of its workforce in a bid to conserve cash as it tries to get...
ReWalk Robotics plans Q2 launch in India
ReWalk Robotics plans to launch its wearable robotic exoskeleton device in India by the 2nd quarter...
Defense Dept. renews $77m Philips contract
Royal Philips wins another year on its $77 million contract with the U.S. Defense Dept. for patient...
Top News Stories